MGTA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MGTA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Research & Development is the aggregate amount of research and development expenses during the year. Magenta Therapeutics's Research & Development for the three months ended in Jun. 2023 was $0.14 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was $35.13 Mil.
The historical data trend for Magenta Therapeutics's Research & Development can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Magenta Therapeutics Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Research & Development | Get a 7-Day Free Trial | 41.34 | 59.21 | 50.62 | 46.77 | 55.14 |
Magenta Therapeutics Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Research & Development | Get a 7-Day Free Trial | 11.60 | 11.20 | 15.79 | 8.00 | 0.14 |
This is the expense the company spent on research and development.
Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $35.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Magenta Therapeutics (NAS:MGTA) Research & Development Explanation
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Thank you for viewing the detailed overview of Magenta Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Evan Harwin | director, 10 percent owner | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Tomas Kiselak | director, 10 percent owner | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Fairmount Funds Management Llc | director, 10 percent owner | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Edward Carr | officer: CHIEF ACCOUNTING OFFICER | 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
Ryan Savitz | officer: CHIEF FINANCIAL OFFICER | 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036 |
Lei Meng | director | 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036 |
Simrat Randhawa | officer: Chief Medical Officer | 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036 |
Avidity Partners Management Lp | director | 2828 N HARWOOD STREET, SUITE 1220, DALLAS TX 75201 |
Marino Garcia | director, officer: CEO and President | C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVENUE, SUITE 2012, NEW YORK NY 10170 |
Adam M Veness | officer: See Remarks | C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036 |
Moulder Leon O Jr | director | C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Paula Soteropoulos | director | 49 WINONA STREET, PEABODY MA 01960 |
Jonathan Violin | director | 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087 |
Third Rock Ventures Iv, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Michael Vasconcelles | director | C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140 |
From GuruFocus
By sperokesalga sperokesalga • 05-10-2023
By Business Wire Business Wire • 05-03-2023
By Business Wire Business Wire • 03-03-2022
By PRNewswire PRNewswire • 05-04-2023
By Value_Insider Value_Insider • 11-03-2022
By GuruFocus Research • 11-14-2023
By Value_Insider Value_Insider • 11-03-2022
By Business Wire Business Wire • 05-16-2022
By Business Wire Business Wire • 11-04-2021
By Business Wire Business Wire • 03-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.